Coral Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 14, 2025, 10:45 pm

Quick Insight

Coral Laboratories Ltd, a pharmaceutical company, currently trades at a price of 556 with a market capitalization of 198 crore and a P/E ratio of 8.02. With a healthy ROE of 13.1% and ROCE of 17.4%, the company demonstrates efficient capital utilization. Operating profit margin stands at 9.56%, indicating operational efficiency. The company's low borrowings of ₹4Cr and a high interest coverage ratio of 362.17x reflect a strong financial position. However, the absence of FII holdings and low DII participation raise questions about institutional investor confidence. With a majority promoter holding of 71.51% and a P/BV ratio of 1.25x, Coral Laboratories Ltd presents a stable investment opportunity, but efforts to attract institutional investors may enhance market sentiment and valuation.

Competitors of Coral Laboratories Ltd

All Competitor Stocks of Coral Laboratories Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:25 am

Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 28.13 Cr.. The value appears strong and on an upward trend. It has increased from 22.99 Cr. (Dec 2024) to 28.13 Cr., marking an increase of 5.14 Cr..
• For Expenses, as of Mar 2025, the value is 25.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.67 Cr. (Dec 2024) to 25.44 Cr., marking an increase of 8.77 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.69 Cr.. The value appears to be declining and may need further review. It has decreased from 6.32 Cr. (Dec 2024) to 2.69 Cr., marking a decrease of 3.63 Cr..
• For OPM %, as of Mar 2025, the value is 9.56%. The value appears to be declining and may need further review. It has decreased from 27.49% (Dec 2024) to 9.56%, marking a decrease of 17.93%.
• For Other Income, as of Mar 2025, the value is 1.71 Cr.. The value appears to be declining and may need further review. It has decreased from 2.52 Cr. (Dec 2024) to 1.71 Cr., marking a decrease of 0.81 Cr..
• For Interest, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
• For Depreciation, as of Mar 2025, the value is 0.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.50 Cr. (Dec 2024) to 0.51 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Mar 2025, the value is 3.85 Cr.. The value appears to be declining and may need further review. It has decreased from 8.32 Cr. (Dec 2024) to 3.85 Cr., marking a decrease of 4.47 Cr..
• For Tax %, as of Mar 2025, the value is 26.49%. The value appears to be increasing, which may not be favorable. It has increased from 26.08% (Dec 2024) to 26.49%, marking an increase of 0.41%.
• For Net Profit, as of Mar 2025, the value is 2.83 Cr.. The value appears to be declining and may need further review. It has decreased from 6.14 Cr. (Dec 2024) to 2.83 Cr., marking a decrease of 3.31 Cr..
• For EPS in Rs, as of Mar 2025, the value is 7.92. The value appears to be declining and may need further review. It has decreased from 17.19 (Dec 2024) to 7.92, marking a decrease of 9.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:02 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:31 pm

Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 198.00 Cr., marking an increase of 24.00 Cr..
• For Borrowings, as of Mar 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 4.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be improving (decreasing). It has decreased from 28.00 Cr. (Mar 2024) to 25.00 Cr., marking a decrease of 3.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 229.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2024) to 23.00 Cr., marking a decrease of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Mar 2024) to 52.00 Cr., marking an increase of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2024) to 152.00 Cr., marking an increase of 20.00 Cr..
• For Total Assets, as of Mar 2025, the value is 229.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..

Notably, the Reserves (198.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
• For Diluted EPS (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
• For Cash EPS (Rs.), as of Mar 22, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 21) to 73.24, marking an increase of 23.52.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 563.19. It has increased from 496.83 (Mar 21) to 563.19, marking an increase of 66.36.
• For Dividend / Share (Rs.), as of Mar 22, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 21) to 1.50, marking a decrease of 0.50.
• For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 321.91. It has increased from 234.17 (Mar 21) to 321.91, marking an increase of 87.74.
• For PBDIT / Share (Rs.), as of Mar 22, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 21) to 98.94, marking an increase of 34.92.
• For PBIT / Share (Rs.), as of Mar 22, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 21) to 93.31, marking an increase of 34.82.
• For PBT / Share (Rs.), as of Mar 22, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 21) to 90.89, marking an increase of 32.86.
• For Net Profit / Share (Rs.), as of Mar 22, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 21) to 67.61, marking an increase of 23.42.
• For PBDIT Margin (%), as of Mar 22, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 21) to 30.73, marking an increase of 3.40.
• For PBIT Margin (%), as of Mar 22, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 21) to 28.98, marking an increase of 4.01.
• For PBT Margin (%), as of Mar 22, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 21) to 28.23, marking an increase of 3.45.
• For Net Profit Margin (%), as of Mar 22, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 21) to 21.00, marking an increase of 2.13.
• For Return on Networth / Equity (%), as of Mar 22, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 21) to 12.00, marking an increase of 3.11.
• For Return on Capital Employeed (%), as of Mar 22, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 21) to 16.30, marking an increase of 4.75.
• For Return On Assets (%), as of Mar 22, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 21) to 10.52, marking an increase of 2.85.
• For Total Debt / Equity (X), as of Mar 22, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 21) to 0.01, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 22, the value is 0.52. It has increased from 0.44 (Mar 21) to 0.52, marking an increase of 0.08.
• For Current Ratio (X), as of Mar 22, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 21) to 7.07, marking an increase of 0.89.
• For Quick Ratio (X), as of Mar 22, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 21) to 6.68, marking an increase of 1.11.
• For Inventory Turnover Ratio (X), as of Mar 22, the value is 3.85. This value is below the healthy minimum of 4. It has increased from 2.87 (Mar 21) to 3.85, marking an increase of 0.98.
• For Interest Coverage Ratio (X), as of Mar 22, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 21) to 362.17, marking a decrease of 113,994.33.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 21) to 256.38, marking a decrease of 79,507.12.
• For Enterprise Value (Cr.), as of Mar 22, the value is 174.27. It has increased from 71.40 (Mar 21) to 174.27, marking an increase of 102.87.
• For EV / Net Operating Revenue (X), as of Mar 22, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 21) to 1.52, marking an increase of 0.67.
• For EV / EBITDA (X), as of Mar 22, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 21) to 4.93, marking an increase of 1.81.
• For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
• For Price / BV (X), as of Mar 22, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 21) to 1.25, marking an increase of 0.51.
• For Price / Net Operating Revenue (X), as of Mar 22, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 21) to 2.18, marking an increase of 0.59.
• For EarningsYield, as of Mar 22, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 21) to 0.09, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness